Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-3305
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production ; volume:11 ; number:1 ; day:27 ; month:12 ; year:2018 ; pages:1-10 ; date:12.2018
Parasites & vectors ; 11, Heft 1 (27.12.2018), 1-10, 12.2018
- Urheber
-
Guidi, Alessandra
Saccoccia, Fulvio
Gennari, Nadia
Gimmelli, Roberto
Nizi, Emanuela
Lalli, Cristiana
Paonessa, Giacomo
Papoff, Giuliana
Bresciani, Alberto
Ruberti, Giovina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13071-018-3268-8
- URN
-
urn:nbn:de:101:1-2019021416013003555640
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Guidi, Alessandra
- Saccoccia, Fulvio
- Gennari, Nadia
- Gimmelli, Roberto
- Nizi, Emanuela
- Lalli, Cristiana
- Paonessa, Giacomo
- Papoff, Giuliana
- Bresciani, Alberto
- Ruberti, Giovina
- SpringerLink (Online service)
Ähnliche Objekte (12)
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Synthesis and Characterization of Histone Deacetylase (HDAC) Inhibitors and PROTACs
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
The histone deacetylase (HDAC) Rpd3 antagonizes heterochromatin formation at telomeres in Saccharomyces cerevisiae
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Synthesis and Characterization of Histone Deacetylase (HDAC) Inhibitors and PROTACs
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
The histone deacetylase (HDAC) Rpd3 antagonizes heterochromatin formation at telomeres in Saccharomyces cerevisiae
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Synthesis and Characterization of Histone Deacetylase (HDAC) Inhibitors and PROTACs
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
The histone deacetylase (HDAC) Rpd3 antagonizes heterochromatin formation at telomeres in Saccharomyces cerevisiae
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo